$OTLK +13% 🚀 🔹 Momentum building after FDA granted its appeal for ONS-5010 / LYTENAVA 🔹 FDA says substantial evidence of effectiveness has been established f

$OTLK +13% 🚀 🔹 Momentum building after FDA granted its appeal for ONS-5010 / LYTENAVA 🔹 FDA says substantial evidence of effectiveness has been established for wet AMD treatment 👀 🔹 Company plans to resubmit BLA in June 2026 🔹 Biotech name focused on ophthalmology — huge market if they finally…